{"DataElement":{"publicId":"4379852","version":"1","preferredName":"Contraception Agreement Female Code Indicator","preferredDefinition":"The coded yes/no/not applicable coded indicator relating to the patient's agreement to use effective contraception during protocol treatment.","longName":"CTCPT_AG_FM_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2014053","version":"1","preferredName":"Contraception Agreement","preferredDefinition":"the patient's agreement to use effective contraception during protocol treatment.","longName":"CONTRACEPTION_AGR","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2725194","version":"1","preferredName":"Contraception","preferredDefinition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"C37932","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contraception","conceptCode":"C37932","definition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"448E87D9-8E4A-47E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-25","modifiedBy":"ONEDATA","dateModified":"2008-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2520617","version":"1","preferredName":"Agreement","preferredDefinition":"1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)","longName":"C25369","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agreement","conceptCode":"C25369","definition":"The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DFE6E80-0641-12A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-21","endDate":null,"createdBy":"AYANLOWA","dateCreated":"2006-09-21","modifiedBy":"ONEDATA","dateModified":"2006-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008542","version":"1","preferredName":"Reproduction","preferredDefinition":"the patient's ability to conceive or nurse offspring and/or their current reproductive status.","longName":"REPRODUCTION","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227DAE6-EC15-4A7D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B318870A-C908-3702-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876423","version":"1","longName":"Consents & Contraceptive Guidelines","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"CTCPT_AG_FM_COD_IND","type":"USED_BY","context":"Theradex"},{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Does female patient of childb","type":"Preferred Question Text","description":"Does female patient of childbearing potential, agree to use an adequate method of contraception throughout the study and for up to 12 weeks after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use adequate contraception prior to study entry and for the duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does female patient of childbearing potential, agree to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use adequate contraception, prior to study entry, for duration of study participation and for 23 weeks after the last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use two forms of contraception, prior to study entry, for duration of study participation and for 23 weeks after the last dose nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use adequate contraception prior to study entry, for the duration of study participation and for 6 months after completion of the study?","url":null,"context":"Theradex"},{"name":"NRG_CRF text","type":"Alternate Question Text","description":"If the patient is of child bearing potential, has she agreed to use two forms of birth control?","url":null,"context":"NRG"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient, female of childbearing potential, agree to commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide and also agree to ongoing pregnancy testing?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does female patient of childbearing potential, who is sexually active, agree to use a medically acceptable form of contraception throughout the study and for up to 6 months after the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does woman of child bearing potential agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 6 months after completion VX-970 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, does she agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [e.g., USPI, SmPC, etc.) after the last dose of study drug, OR patient agrees to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use adequate contraception, prior to study entry, for duration of study participation and for 5 months after last dose of adezolizumab and for 6 months after completion of bevacizumab therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Is female patient, postmenopausal for at least 1 year before the screening visit, OR is surgically sterile, OR if of childbearing potential, agrees to practice 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [e.g., USPI, SmPC, etc.;]) after the last dose of study drug, OR agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient is female of childbearing potential (fertile), does patient agree to use adequate contraceptive measures during and for 6 weeks after AZD9291 (osimertinib)?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does female patient of childbearing potential who is sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab Monotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use adequate contraception prior to study entry, for the duration of study participation and for 5 weeks after receiving the last dose of AMG 232?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, does patient agree to use two forms of contraception or complete abstinence prior to study entry, for duration of study participation and for 5 months (150 days) after the last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, does patient agree to use two forms of contraception, prior to study entry, for duration of study participation and for 4 months after coming off study?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% per year during the treatment period and for 30 days after tazemetostat discontinuation?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, does patient agree to use effective contraception from 14 days prior to randomization, throughout the treatment period, and for 4 months after the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Is patient, women of childbearing potential, postmenopausal or have evidence of non-pregnant status as confirmed by negative urine or serum pregnancy test within 7 days prior to start of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Does female patient, of child-bearing or non-child bearing potential, agree to use adequate contraceptive measures from 2 weeks prior to the study and until 1 month after study treatment discontinuation?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does female patient who is not of child-bearing potential or fertile female of childbearing potential, agree to use adequate contraceptive measures from 2 weeks prior to the study and until 1 month after study treatment discontinuation?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use adequate contraception, prior to study entry, for duration of study participation and for 7 months after the last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, does she agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 120 days (or longer, as mandated by local labeling (e.g., USPI, SmPC, etc.) after the last dose of study drug, OR patient agrees to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If patient is woman of child bearing potential, does patient agree to use highly effective contraception during the study and for 1 month after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and their partners, agree to use two (2) highly effective forms of contraception throughout study participation and for at least one (1) month after the last dose of olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, during study participation, and for a minimum of 5 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does woman of child bearing potential agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 6 months after completion M6620 (VX-970) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use adequate contraception, prior to study entry, for duration of study participation and for 5 months after last dose of atezolizumab and for 6 months after completion of bevacizumab therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does female patient of childbearing, receiving nivolumab, agree to adhere to contraception for a period of 5 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use adequate contraception?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, during study participation, and for 5 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Does female patient of childbearing, receiving nivolumab, agree to use adequate contraception prior to study, during study participation and will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Is patient postmenopausal or if of childbearing potential is there evidence of non-pregnant status as confirmed by negative urine or serum pregnancy test within 7 days prior to start of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Does female patient of childbearing potential agree to use one highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Is female patient, postmenopausal for at least 1 year before the screening visit, OR is surgically sterile, OR if of childbearing potential, agrees to practice 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 4 months after the last dose of ixazomib and pevonedistat, OR agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"If female, is patient post-menopausal (age-related amenorrhea greater than or equal to 12 consecutive months or follicle-stimulating hormone greater than 40 mIU/mL), for at least 1 year before the screening visit OR surgically sterile (i.e., has undergone hysterectomy or bilateral oophorectomy), OR if of child bearing potential agrees to practice 1 highly effective method and 1 additionally effective (barrier) method of contraception at the same time from the time of signing the informed consent through 4 months after the last dose of study drug OR agrees to practice true abstinence if this is the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use appropriate contraception for duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use adequate contraception, prior to study entry, for duration of study participation and for 5 months after the last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use highly effective contraception during the study and for 6 months after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use effective method of contraception during the study and for 3 months after study completion?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Is female patient, postmenopausal for at least 1 year before the screening visit, OR is surgically sterile, OR if of childbearing potential, agrees to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, OR agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"If female is postmenopausal or have evidence of non-childbearing potential, are the following criteria met:  amenorrheic for 1 year or more following cessation of exogenous hormonal treatments, luteinizing hormone and follicle stimulating hormone levels in post-menopausal range for women under 50, radiation-induced oophorectomy with last menses greater than 1 year ago,  chemotherapy-induced menopause with greater than 1 year interval since last menses or surgical sterilization (bilateral oophorectomy or hysterectomy)?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use adequate contraception prior to study entry, for the duration of study participation and for 5 weeks after receiving the last dose of KRT-232 (AMG 232)?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"If patient is of childbearing potential and sexually active, does patient and their partners agree to use, two reliable and acceptable methods of contraception simultaneously prior to study entry, during the treatment period and for 6 months after last dose of radium-223 dichloride?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use adequate contraception, prior to study entry, for duration of study participation and for 5 months after the last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"If patient is female of child-bearing potential, patient will not use any hormonal means of birth control such as oral, injectable, dermal, subdermal or topical contraceptives?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient commit to either abstaining continuously from heterosexual sexual intercourse or agree to use 2 forms of adequate contraception or continuously abstain from the time of informed consent for the duration of study participation through 5 weeks after receiving the last dose of KRT-232 (AMG 232), lenalidomide, or carfilzomib?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does female patient of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation and for 120 days after completion of MEDI4736 (durvalumab) and tremelimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"If patient is women of childbearing potential does patient agree to use birth control or remain abstinent for the duration of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"If patient is women of childbearing potential does patient agree to use birth control or remain abstinent for the duration of the study and for at least 28 days following the last doe of tocilizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"If patient is a woman of child-bearing potential, patient agrees to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 2 weeks prior to study drug exposure, the duration of study participation, and for 1 month after completing treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, patient agrees to use an effective method of contraception, prior to study entry, for duration of study treatment and for 5 months after the last dose of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and male partner, agree to use a double-barrier method of birth control or practice continuous abstinence from heterosexual contact throughout the study and for seven months after the date of their last treatment with Lutetium Lu 177 Dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Does women of child-bearing potential and their partners, who are sexually active, agree to the use of one highly effective form of contraception and their partner must use a male condom prior to study entry, for the duration of study participation, and for 6 months after the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, will patient use an adequate method to avoid pregnancy for 5 months after the last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Does female patient agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of the study participation and for at least 6 months after the last dose of study drugs?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Does female patient of child-bearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation, and 3 months after completion of erdafitinib and enfortumab vedotin administration?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"If patient is female of child-bearing potential, will patient use contraceptive methods with a failure rate of less than or equal to 1% used in combination with the barrier method?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential (WOCBP), patient agrees to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of less than 1% per year during the treatment period, for 5 months after the last dose of pembrolizumab and 28 days after the last dose of ipatasertib, and agrees to refrain from donating eggs during this same period?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, does patient agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of less than 1% per year during the treatment period and for at least 28 days after the last dose of ipatasertib and agree to refrain from donating eggs during this same period?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential, their male partner and male patients, agree to use contraception from the time of the screening pregnancy test, continuing for the duration of study participation, and for 3 months after completing the study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"If female patient is on hormone replacement therapy (HRT) and menopausal status is in doubt, has patient agreed to use one of the contraception methods outlined for women of child-bearing potential OR discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"If patient is a woman of child-bearing potential, does patient agree to use adequate contraception prior to study entry, for the duration of study participation, for at least 1 month after the last dose of neratinib, or at least 7 months after the last dose of DS-8201a, whichever is longer?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"If patient is a woman of child-bearing potential, does patient agree to use adequate contraception prior to study entry and for the duration of study participation and for 6 months after the last dose of the study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"If patient is women of child-bearing potential, does patient agree to use adequate contraception (hormonal birth control or abstinence) prior to study entry, for the duration of study participation, and for 6 months following completion of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Is female patient of childbearing potential willing to use an adequate method of contraception as outlined in Section 6.6 (Contraception and Pregnancy) for the course of the study through 6 months after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), or agrees to practice true abstinence?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient agree to use 2 forms of contraception from screening visit until 120 days following the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does woman of childbearing potential (WOCBP), receiving nivolumab, agree to continue contraception for a period of 5 months after the last dose of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"If patient is a women of child-bearing potential, does patient agree to use adequate contraception prior to study entry and, for the duration of study participation, and 6 months after completion of M1774 and avelumab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, patient agrees to remain abstinent or use contraceptive measures with a failure rate of 1% per year during the treatment period, and agrees to refrain from donating eggs for 3 months after the final dose of mosunetuzumab, 3 months after the final dose of polatuzumab vedotin, and 1 month after the last dose of lenalidomide?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6CAE-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeDescription":"2020-7-27 AQT added for protocol 10389. AK Theradex_ghd_07-02-14","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"}}